TNKS
Poly [ADP-ribose] polymerase tankyrase-1
As of the edition of 20 October 2026, TNKS (poly [ADP-ribose] polymerase tankyrase-1, UniProt O95271) has 2 drugs tested at it and 3 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O95271
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 42
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Hormones; Skin and connective tissue; Blood and lymph; Digestive system; Immune system
- Registered trials of its drugs
- 13
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nesuparib | Active | Phase 2 | none listed |
| 2X-121 | Active | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 3 |
| Total on the list | 3 |